FDA label bb156209-7832-4d16-9fe9-ab0d919f3172

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

SPL set ID
74a4c1b4-ea1e-4a02-ae62-a850f8a800e2
SPL ID
bb156209-7832-4d16-9fe9-ab0d919f3172
Version
11
Effective date
2010-12-27
Source export date
2026-10-12
Source partition
13
Source file
https://download.open.fda.gov/drug/label/drug-label-0013-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-10-12/b8dac220ac9fc8ffb4d86c6e00ece30169fc4575ca0cc92e5c9ce1a524fb0249/drug-label-0013-of-0014.json.zip
Source manifest SHA-256
7e6b178df8f32cac9a78e0f5d09c588344509b04fe41effb1dde9102e2a45be6
Import run
20261013T011858Z
Imported at
2026-10-13 03:03:29

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

WARNINGS AND PRECAUTIONS Do not exceed recommended dosage. This drug may make you dizzy or drowsy or cause blurred vision; use caution while driving, using machinery, or doing any activity that requires alertness or clear vision. Limit alcohol consumption. Cross sensitivity and/or related problems: Patients intolerant of other belladonna alkaloids or other salicylates may be intolerant of this medication also. Delay in gastric emptying could complicate the management of gastric ulcers. There have been no studies to establish the safety or prolonged use of this product in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential. Pregnancy: Teratogenic Effects. Pregnancy Category C: Hyoscyamine Sulfate and Methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether Phosenamine capsules cause fetal harm when administered to a pregnant woman or can affect reproduction. Phosenamine capsules should be given to a pregnant woman only if clearly needed. Nursing Mothers: Problems in humans have not been documented; however, Methenamine and traces of Hyoscyamine Sulfate are excreted in breast milk. Phosenamine capsules should be given to a lactating woman only if clearly needed. Discuss the risks and benefits with your doctor. Pediatric Use: Infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids (Hyoscyamine Sulfate). This product contains salicylate, which is related to aspirin. Children and teenagers should not take aspirin, aspirin-containing or aspirin-related medications if they have chickenpox, influenza, or any undiagnosed illness without first consulting a doctor. A rare but serious illness known as Reye’s syndrome may occur. This medication is not recommended for children younger than 6 years. Geriatric Use: Use with caution in elderly patients as they may respond to usual doses of Hyoscyamine Sulfate excitement, agitation, drowsiness or confusion.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 1 matching rows.

adverse reactions

ADVERSE REACTIONS Cardiovascular: rapid heartbeat, flushing Central Nervous System: blurred vision dizziness, drowsiness Genitourinary: difficulty urinating, acute urinary retention Gastrointestinal: dry mouth, nausea and vomiting Respiratory: shortness of breath or trouble breathing Serious allergic reactions to this drug are rare. Seek immediate medical attention if you notice symptoms of a serious allergic reaction, including itching rash, severe dizziness, swelling or trouble breathing. This medication can cause urine and sometimes stools to turn blue-green. This effect is harmless and will subside after medication is stopped. Call your doctor or physician for medical advice about side effects. The following number does not provide medical advice, but in the U.S. you may report suspected side effects to the FDA at 1-800-FDA-1088.

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.